Systemic MastocytosisSymptoms, Doctors, Treatments, Advances & More
Learn About Systemic Mastocytosis
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Dept Of Transfusion Medicine/Nih Clinical Center
Dean Metcalfe is a Rheumatologist practicing medicine in Bethesda, Maryland. Dr. Metcalfe is rated as an Elite provider by MediFind in the treatment of Systemic Mastocytosis. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Mast Cell Activation Syndrome (MCAS), Systemic Mastocytosis, Urticaria Pigmentosa, and Anaphylaxis.
Domino's Farms
Dr. Akin completed his residency in Internal Medicine and PhD at the University of Louisville, and his Allergy/Immunology fellowship at the NIH Clinical Center, where he also worked as a staff physician and researcher. He was then an Assistant Professor at the University of Michigan and an Associate Professor at Harvard Medical School, where he established and lead the Mastocytosis Center at the Brigham and Women's Hospital in Boston. He is internationally recognized for his work on mast cell disorders and anaphylaxis and is an active member of the AAAAI. Dr. Akin is rated as an Elite provider by MediFind in the treatment of Systemic Mastocytosis. He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Systemic Mastocytosis, Mast Cell Activation Syndrome (MCAS), Anaphylaxis, Urticaria Pigmentosa, and Tissue Biopsy.
Stanford University
Jason Gotlib is a Hematologist practicing medicine in Palo Alto, California. Dr. Gotlib is rated as an Elite provider by MediFind in the treatment of Systemic Mastocytosis. He is also highly rated in 42 other conditions, according to our data. His clinical expertise encompasses Systemic Mastocytosis, Mast Cell Activation Syndrome (MCAS), Myelofibrosis, Bone Marrow Aspiration, and Tissue Biopsy.
Summary: This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by SDT. Parts 1 and 2 will enroll participants with ISM. Participants enrolled in Part 2 will roll over onto Part ...
Summary: Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion of the disease, but patients frequently experience progression of the concomitant myeloid malignancy (i.e. the AHN). Using a combination approach to treat both aspects of t...